NeoGenomics, Inc. (NEO) News
Track canonical SquawkNews coverage tagged to NEO, NeoGenomics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
NeoGenomics gets Medicare coverage for RaDaR ST
NeoGenomics received Medicare coverage for RaDaR ST for immunotherapy treatment response monitoring.
EQUITY | Aug 26, 2026, 08:17 PM UTC
H
NEO PT Raised to $19
NEO price target raised to $19
EQUITY | Jul 29, 2026, 01:20 PM UTC
L
NEO Q2 adj. EPS $0.05 vs. est. $0.03; adj. gross margin 48%; adjusted EBITDA $14Mm vs est $12.81Mm, up 36% year over year as revenue rose 11
NEO Q2 adj. EPS $0.05 vs. est. $0.03; adj. gross margin 48%; adjusted EBITDA $14Mm vs est $12.81Mm, up 36% year over year as revenue rose 11% to $202Mm vs. $197Mm est.; FY26 outlook raised with revenue guided to $802–$80
EARNINGS | Jul 28, 2026, 08:41 PM UTC
L
NeoGenomics raises FY26 revenue view from $797M-$803M to $802M-$806M
Consensus $800.4M. Raises...
EQUITY | Jul 28, 2026, 08:25 PM UTC
L
NeoGenomics reports Q2 EPS 5c, consensus 3c
Reports Q2 revenue...
EARNINGS | Jul 28, 2026, 08:23 PM UTC
L
NeoGenomics Raises FY2026 Sales Guidance from $797.000M-$803.000M to $802.000M-$806.000M vs $800.433M Est
NeoGenomics (NASDAQ: NEO ) raises FY2026 sales outlook from $797.000 million-$803.000 million to $802.000 million-$806.000 million vs $800.433 million estimate.
EARNINGS | Jul 28, 2026, 08:06 PM UTC
L
NeoGenomics announces settlement of voluntary disclosure to OIG-HHS
NeoGenomics announces settlement of voluntary disclosure to OIG-HHS
EQUITY | Jul 20, 2026, 09:27 PM UTC
L
NeoGenomics launches FDA-approved PTEN IHC prostate Cancer ompanion diagnostic
NeoGenomics announced the launch of PTEN IHC CDx, the first immunohistochemistry companion diagnostic test approved by the FDA for patients with prostate adenocarcinoma. The test identifies PTEN protein loss, also known
EQUITY | Jul 09, 2026, 11:10 AM UTC